Eli Lilly | LLY - Cash And Equivalent


Eli Lilly reported $5.28B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Abbott USD 6.8B 1.72B Mar/2026
ALKERMES USD 351.55M 37.02M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Baxter International USD 2.02B 51M Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Drreddys Laboratories INR 18.66B 9.65B Dec/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Glaxosmithkline GBP 3.3B 303M Sep/2025
J&J USD 21.69B 1.98B Mar/2026
Medtronic USD 1.15B 135M Dec/2025
Merck USD 5.33B 9.24B Mar/2026
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Novartis USD 9.56B 2.9B Sep/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Perrigo USD 531.6M 99.5M Dec/2025
Pfizer USD 1.7B 561M Mar/2026
Phibro Animal Health USD 54.93M 557K Mar/2026
Prestige Brands USD 63.87M 1.5M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
United Therapeutics USD 1.28B 277.4M Mar/2026
Zoetis USD 1.94B 369M Mar/2026